Lupin plans expansion, eyes Europe growth via acquisitions and launches

The pharma major acquired a portfolio of central nervous drug system drugs, including NaMuscla, through its acquisition of German drug maker Temmler Pharma in 2015

Lupin is planning launches and product acquisitions to give a fillip to its European business. “The company is exploring potential products that treat underserved neurological conditions,” Lupin’s President in Europe and Middle East Thierry Volle said. 

Another growth driver would be product launches, including biosimilar Etanercept, to treat rheumatoid arthritis and a rare muscle disorder drug called NaMuscla. Both the launches are expected in 2019.

Recently, Lupin received a positive opinion from European regulator, which recommended marketing approval to NaMuscla –